Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | FKBP1A | P62942 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.47 |
| ▸ | PREP | P48147 | 3/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2721261 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19FKBP1A | |
| SCHEMBL3114029 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19FKBP1A | |
| SCHEMBL1488503 | 0.90 | FKBP1A (0.50) | SMN1; SMN2NPC1RAB9ACYP2C19FKBP1A | |
| SCHEMBL1488515 | 0.90 | FKBP1A (0.50) | SMN1; SMN2NPC1RAB9ACYP2C19FKBP1A | |
| SCHEMBL1488666 | 0.90 | FKBP1A (0.50) | SMN1; SMN2NPC1RAB9ACYP2C19FKBP1A | |
| SCHEMBL3835409 | 0.88 | ACE2 (0.49) | SMN1; SMN2NPC1RAB9ACYP2C19FKBP1A | |
| SCHEMBL1488893 | 0.79 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL1488901 | 0.78 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL18089695 | 0.77 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL1488726 | 0.77 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1RAB9ACYP2C19FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140275527-A1 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases | EXELIXIS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| US-11597699-B2 | MEK inhibitors and methods of their use | EXELIXIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20200283383-A1 | MEK Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2020-09-10 | — | — | US | disclosed |
| US-20200031770-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | EXELIXIS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20190144382-A1 | MEK Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2019-05-16 | — | — | US | disclosed |
| US-20170166523-A9 | MEK Inhibitors And Methods Of Their Use | EXELIXIS, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20150141399-A1 | MEK Inhibitors And Methods Of Their Use | EXELIXIS INC (US) | 2015-05-21 | — | — | US | disclosed |
| US-20140275527-A1 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases | EXELIXIS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8362002-B2 | Azetidines as MEK inhibitors for the treatment of proliferative diseases | EXELIXIS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-7803839-B2 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | EXELIXIS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20090156576-A1 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | EXELIXIS INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166523-A9 | MEK Inhibitors And Methods Of Their Use | BRAF, NRAS, MAP3K1 | SMN1; SMN2 3819/4885NPC1 2673/4885RAB9A 904/4885 |
| US-20200283383-A1 | MEK Inhibitors and Methods of Their Use | BRAF, NRAS, MAP3K20 | SMN1; SMN2 3755/4885NPC1 2632/4885RAB9A 872/4885 |
| US-20150141399-A1 | MEK Inhibitors And Methods Of Their Use | BRAF, NRAS, MAP3K1 | SMN1; SMN2 3819/4885NPC1 2673/4885RAB9A 904/4885 |
| US-20090156576-A1 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | NRAS, BRAF, KRAS | SMN1; SMN2 3569/4885NPC1 1452/4885RAB9A 899/4885 |
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | SMN1; SMN2 3846/4885NPC1 1514/4885RAB9A 1196/4885 |
| US-20190144382-A1 | MEK Inhibitors and Methods of Their Use | BRAF, NRAS, MAP3K20 | SMN1; SMN2 3755/4885NPC1 2632/4885RAB9A 872/4885 |
| US-20140275527-A1 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases | NRAS, BRAF, KRAS | SMN1; SMN2 2697/4885NPC1 1367/4885RAB9A 209/4885 |
| US-11597699-B2 | MEK inhibitors and methods of their use | BRAF, NRAS, MAP3K20 | SMN1; SMN2 3755/4885NPC1 2632/4885RAB9A 872/4885 |
| US-20200031770-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | BRAF, NRAS, MAP3K20 | SMN1; SMN2 3755/4885NPC1 2632/4885RAB9A 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.